ACEIs significantly increased the risk of cough compared to placebo (RR 2.21; 95% CI 2.05-2.39), ARBs (RR 3.2), and CCBs (RR 5.30), with moexipril ranking highest for inducing cough.
Meta-Analysis (n=45,420)
Do ACEIs increase the risk of cough compared to placebo, ARBs, or CCBs?
This network meta-analysis confirms that ACEIs significantly increase the risk of cough compared to placebo, ARBs, and CCBs, with moexipril having the highest risk and spirapril the lowest.
Effect estimate: RR 2.21 (95% CI 2.05-2.39)
Studies have shown that angiotensin converting enzyme inhibitors (ACEIs) are superior in primary and secondary prevention for cardiac mortality and morbidity to angiotensin receptor blocker (ARBs). One of the common side effects from ACEI is dry cough. The aims of this systematic review, and network meta-analysis are to rank the risk of cough induced by different ACEIs and between ACEI and placebo, ARB or calcium channel blockers (CCB). We performed a systematic review, and network meta-analysis of randomized controlled trials to rank the risk of cough induced by each ACEI and between ACEI and placebo, ARB or CCB. A total of 135 RCTs with 45,420 patients treated with eleven ACEIs were included in the analyses. The pooled estimated relative risk (RR) between ACEI and placebo was 2.21 (95% CI: 2.05-2.39). ACEI had more incidences of cough than ARB (RR 3.2; 95% CI: 2.91, 3.51), and pooled estimated of RR between ACEI and CCB was 5.30 (95% CI: 4.32-6.50) Moexipril ranked as number one for inducing cough (SUCRA 80.4%) and spirapril ranked the least (SUCRA 12.3%). The order for the rest of the ACEIs are as follows: ramipril (SUCRA 76.4%), fosinopril (SUCRA 72.5%), lisinopril (SUCRA 64.7%), benazepril (SUCRA 58.6%), quinapril (SUCRA 56.5%), perindopril (SUCRA 54.1%), enalapril (SUCRA 49.7%), trandolapril (SUCRA 44.6%) and, captopril (SUCRA 13.7%). All ACEI has the similar risk of developing a cough. ACEI should be avoided in patients who have risk of developing cough, and an ARB or CCB is an alternative based on the patient's comorbidity.
Hu et al. (Fri,) conducted a meta-analysis in Cardiac mortality and morbidity prevention (n=45,420). Angiotensin-converting enzyme inhibitors (ACEIs) vs. Placebo, ARBs, or CCBs was evaluated on Risk of cough (RR 2.21, 95% CI 2.05-2.39). ACEIs significantly increased the risk of cough compared to placebo (RR 2.21; 95% CI 2.05-2.39), ARBs (RR 3.2), and CCBs (RR 5.30), with moexipril ranking highest for inducing cough.